Literature DB >> 30866031

Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Rimas V Lukas, Derek A Wainwright, Erik Ladomersky, Sean Sachdev, Adam M Sonabend, Roger Stupp.   

Abstract

Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classification of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumor-treating fields will be presented. Pivotal studies defining our current standard of care will be highlighted, as will key ongoing trials that may influence our management of glioblastoma in the near future.

Entities:  

Mesh:

Year:  2019        PMID: 30866031      PMCID: PMC7278092     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  116 in total

1.  Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.

Authors:  Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study.

Authors:  E Susan Amirian; Renke Zhou; Margaret R Wrensch; Sara H Olson; Michael E Scheurer; Dora Il'yasova; Daniel Lachance; Georgina N Armstrong; Lucie S McCoy; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Jonine L Bernstein; Ryan T Merrell; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Beatrice S Melin; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Temozolomide: mechanisms of action, repair and resistance.

Authors:  Jihong Zhang; Malcolm F G Stevens; Tracey D Bradshaw
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

5.  Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Authors:  Alexandre Carpentier; Michael Canney; Alexandre Vignot; Vincent Reina; Kevin Beccaria; Catherine Horodyckid; Carine Karachi; Delphine Leclercq; Cyril Lafon; Jean-Yves Chapelon; Laurent Capelle; Philippe Cornu; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Sci Transl Med       Date:  2016-06-15       Impact factor: 17.956

6.  Language outcomes after resection of dominant inferior parietal lobule gliomas.

Authors:  Derek G Southwell; Marco Riva; Kesshi Jordan; Eduardo Caverzasi; Jing Li; David W Perry; Roland G Henry; Mitchel S Berger
Journal:  J Neurosurg       Date:  2017-01-06       Impact factor: 5.115

7.  Corticosteroids compromise survival in glioblastoma.

Authors:  Kenneth L Pitter; Ilaria Tamagno; Kristina Alikhanyan; Amira Hosni-Ahmed; Siobhan S Pattwell; Shannon Donnola; Charles Dai; Tatsuya Ozawa; Maria Chang; Timothy A Chan; Kathryn Beal; Andrew J Bishop; Christopher A Barker; Terreia S Jones; Bettina Hentschel; Thierry Gorlia; Uwe Schlegel; Roger Stupp; Michael Weller; Eric C Holland; Dolores Hambardzumyan
Journal:  Brain       Date:  2016-03-28       Impact factor: 13.501

8.  Acceptance and compliance of TTFields treatment among high grade glioma patients.

Authors:  Julia Onken; Franziska Staub-Bartelt; Peter Vajkoczy; Martin Misch
Journal:  J Neurooncol       Date:  2018-04-11       Impact factor: 4.130

9.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.

Authors:  Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak
Journal:  Genome Res       Date:  2015-02-03       Impact factor: 9.043

10.  Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Martin J B Taphoorn; Linda Dirven; Andrew A Kanner; Gitit Lavy-Shahaf; Uri Weinberg; Sophie Taillibert; Steven A Toms; Jerome Honnorat; Thomas C Chen; Jan Sroubek; Carlos David; Ahmed Idbaih; Jacob C Easaw; Chae-Yong Kim; Jordi Bruna; Andreas F Hottinger; Yvonne Kew; Patrick Roth; Rajiv Desai; John L Villano; Eilon D Kirson; Zvi Ram; Roger Stupp
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

View more
  33 in total

Review 1.  Clinical neuro-oncology for the neurologist.

Authors:  Rimas V Lukas; Jennie W Taylor; Sylvia C Kurz; Nimish A Mohile
Journal:  Neurol Clin Pract       Date:  2020-10

2.  Blockade of Nuclear Factor-Κb (NF-Κb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells.

Authors:  Ali Nasrollahzadeh; Majid Momeny; Davood Bashash; Hassan Yousefi; Seyed Asadollah Mousavi; Seyed Hamidollah Ghaffari
Journal:  Rep Biochem Mol Biol       Date:  2022-01

3.  ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression.

Authors:  Kang Yang; Lan Luan; Xinyu Li; Xu Sun; Jian Yin
Journal:  J Neurooncol       Date:  2021-11-19       Impact factor: 4.130

Review 4.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

5.  Physical Training Protects Against Brain Toxicity in Mice Exposed to an Experimental Model of Glioblastoma.

Authors:  Amanda K Costa; Luis F B Marqueze; Bruna B Gattiboni; Giulia S Pedroso; Franciane F Vasconcellos; Eduardo B B Cunha; Hanna C Justa; Antonielle B Baldissera; Seigo Nagashima; Lucia de Noronha; Zsolt Radak; Luiz C Fernandes; Ricardo A Pinho
Journal:  Neurochem Res       Date:  2022-07-29       Impact factor: 4.414

6.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

Review 7.  Immunotherapy Against Gliomas: is the Breakthrough Near?

Authors:  Rimas V Lukas; Derek A Wainwright; Craig M Horbinski; Fabio M Iwamoto; Adam M Sonabend
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 8.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

9.  GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo.

Authors:  Urban J Scheuring; Steffi Ritter; Daniel Martin; Gabriele Schackert; Achim Temme; Stefanie Tietze
Journal:  J Neurooncol       Date:  2021-04-15       Impact factor: 4.130

Review 10.  Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.

Authors:  Zachariah P Tritz; Katayoun Ayasoufi; Aaron J Johnson
Journal:  Neurooncol Adv       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.